Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SNTI | US
-0.02
-0.88%
Healthcare
Biotechnology
30/06/2024
21/10/2024
2.26
2.28
2.38
2.20
Senti Biosciences Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202 a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401 a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences Inc. was incorporated in 2016 and is headquartered in South San Francisco California.
View LessValue Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.5%1 month
100.3%3 months
105.0%6 months
123.0%-
-
0.24
0.81
0.41
-0.28
118.91
-
-56.60M
10.35M
10.35M
-
-18.02K
-
-100.00
-111.07
3.95
1.92
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.63
Range1M
1.28
Range3M
1.77
Rel. volume
0.18
Price X volume
11.21K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
RedHill Biopharma Ltd | RDHL | Biotechnology | 8.62 | 11.04M | -1.88% | n/a | 65.80% |
Common Stock | ADXN | Biotechnology | 10.3 | 11.01M | -1.34% | n/a | 0.25% |
Mustang Bio Inc | MBIO | Biotechnology | 0.2935 | 10.93M | 35.00% | n/a | -13.03% |
Jaguar Health Inc | JAGX | Biotechnology | 1.18 | 10.90M | -3.28% | 0.25 | 176.14% |
Alterity Therapeutics Limited | ATHE | Biotechnology | 1.22 | 10.67M | -3.17% | n/a | 1.15% |
XTL Biopharmaceuticals Ltd | XTLB | Biotechnology | 1.955 | 10.65M | -6.32% | n/a | 0.00% |
TransCode Therapeutics Inc. Common Stock | RNAZ | Biotechnology | 0.615 | 10.37M | 0.31% | 0.00 | 17.19% |
KPRX | KPRX | Biotechnology | 3.49 | 10.37M | 0.58% | 0.21 | 0.25% |
GlycoMimetics Inc | GLYC | Biotechnology | 0.16 | 10.32M | 1.01% | n/a | 2.24% |
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.24 | 9.46M | 4.44% | n/a | 704.57% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.28 | 0.53 | Cheaper |
Ent. to Revenue | 118.91 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.24 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 105.01 | 72.80 | Riskier |
Debt to Equity | 0.81 | -1.23 | Expensive |
Debt to Assets | 0.41 | 0.25 | Expensive |
Market Cap | 10.35M | 3.66B | Emerging |